James E Frampton

Summary

Affiliation: Adis International Limited
Country: New Zealand

Publications

  1. ncbi Tramadol/paracetamol
    Karen McClellan
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:1079-86; discussion 1087-8. 2003
  2. ncbi Latanoprost : an update of its use in glaucoma and ocular hypertension
    Caroline M Perry
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs Aging 20:597-630. 2003
  3. ncbi Retigabine: in partial seizures
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 20:601-8; discussion 609-10. 2006
  4. ncbi Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection
    Jamie D Croxtall
    Adis, Auckland, New Zealand
    Drugs 72:847-69. 2012
  5. ncbi Acetylsalicylic acid/esomeprazole fixed-dose combination
    Celeste B Burness
    Adis, Auckland, New Zealand
    Drugs Aging 29:233-42. 2012
  6. ncbi Tapentadol extended release: in adults with chronic pain
    Sheridan M Hoy
    Adis, Auckland, New Zealand
    Drugs 72:375-93. 2012
  7. ncbi Argatroban: a review of its use in the management of heparin-induced thrombocytopenia
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 9:261-82. 2009
  8. ncbi Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension
    Jamie D Croxtall
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs Aging 26:437-46. 2009
  9. ncbi Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy
    Gillian M Keating
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:1239-65. 2009
  10. ncbi Intranasal sumatriptan: in adolescents with migraine
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 19:335-43; discussion 345-6. 2005

Collaborators

Detail Information

Publications484 found, 100 shown here

  1. ncbi Tramadol/paracetamol
    Karen McClellan
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:1079-86; discussion 1087-8. 2003
    ..5/325 mg provided similar efficacy to that of codeine/paracetamol 30/300 mg in patients with chronic back pain in a 4-week, randomised, double-blind trial (a maximum of 10 tablets or capsules per day of the active drug)...
  2. ncbi Latanoprost : an update of its use in glaucoma and ocular hypertension
    Caroline M Perry
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs Aging 20:597-630. 2003
    ..Although preliminary findings are promising, wider clinical experience is required to define the place of latanoprost in the treatment of angle-closure glaucoma...
  3. ncbi Retigabine: in partial seizures
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 20:601-8; discussion 609-10. 2006
    ..Across all three retigabine groups in the large phase II trial, somnolence (20.3%), dizziness (14.6%), confusion (12.3%) and speech disorder (11.3%) were the most frequent CNS-related adverse events...
  4. ncbi Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection
    Jamie D Croxtall
    Adis, Auckland, New Zealand
    Drugs 72:847-69. 2012
    ....
  5. ncbi Acetylsalicylic acid/esomeprazole fixed-dose combination
    Celeste B Burness
    Adis, Auckland, New Zealand
    Drugs Aging 29:233-42. 2012
    ..Low-dose ASA plus esomeprazole treatment was generally well tolerated, with a similar adverse event profile to that seen with low-dose ASA plus placebo...
  6. ncbi Tapentadol extended release: in adults with chronic pain
    Sheridan M Hoy
    Adis, Auckland, New Zealand
    Drugs 72:375-93. 2012
    ..Oral tapentadol ER therapy for up to 24 months was generally well tolerated, with the nature of treatment-emergent adverse events generally similar across the clinical studies...
  7. ncbi Argatroban: a review of its use in the management of heparin-induced thrombocytopenia
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 9:261-82. 2009
    ..However, a small uncontrolled, preliminary study suggests that it may be useful in seriously ill pediatric patients requiring nonheparin anticoagulation...
  8. ncbi Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension
    Jamie D Croxtall
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs Aging 26:437-46. 2009
    ..Moreover, a significantly greater number of patients expressed a preference for brinzolamide/timolol over dorzolamide/timolol. The main ocular adverse event was blurred vision, and was not considered to be a safety issue...
  9. ncbi Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy
    Gillian M Keating
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:1239-65. 2009
    ..Losartan/HCTZ is a well tolerated combination therapy. Thus, losartan/HCTZ remains an important option in the treatment of hypertension, as well as being indicated to reduce stroke risk in patients with hypertension and LVH...
  10. ncbi Intranasal sumatriptan: in adolescents with migraine
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 19:335-43; discussion 345-6. 2005
    ..Taste disturbance occurred more often with intranasal sumatriptan than with placebo [Chart: see text]...
  11. ncbi Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis
    James E Frampton
    Wolters Kluwer Health Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 10:51-72. 2009
    ....
  12. ncbi Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]: profile report
    Susan J Keam
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 22:205-8. 2008
  13. ncbi Alitretinoin: in severe chronic hand eczema
    Karly P Garnock-Jones
    Wolters Kluwer Health Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 69:1625-34. 2009
    ..The most common treatment-emergent adverse events and abnormal laboratory test results were consistent with those previously observed with other oral retinoids and RXR agonists...
  14. ncbi Nesiritide: a review of its use in acute decompensated heart failure
    Gillian M Keating
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:47-70. 2003
    ..Thus, nesiritide is a suitable first-line option for the treatment of patients with acutely decompensated CHF and is a welcome addition in an area where intravenous agents are few...
  15. ncbi Pregabalin: in the treatment of postherpetic neuralgia
    Kate McKeage
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 26:883-92. 2009
    ..Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity...
  16. ncbi Everolimus: in advanced renal cell carcinoma
    Karly P Garnock-Jones
    Adis, Auckland, New Zealand
    Drugs 69:2115-24. 2009
    ..The tolerability profile of everolimus was largely manageable in the phase III trial, with most treatment-related adverse events being of grade 1 or 2 severity...
  17. ncbi Airmax: a multi-dose dry powder inhaler
    Gillian M Keating
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1887-95; discussion 1896-7. 2002
    ..Both adults and children preferred Airmax to Turbuhaler, and more found Airmax easier to use. In one study, the majority of children found learning how to use Airmax trade mark easier than learning how to use Turbuhaler...
  18. ncbi Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection
    Malcolm J M Darkes
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 4:609-30. 2002
    ..pneumoniae infections. In developed countries, the vaccine will be of particular benefit in preventing disabling infections but its impact in developing countries will be more pronounced with the potential to greatly reduce mortality...
  19. ncbi Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer
    Natalie J Carter
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:355-76. 2010
    ....
  20. ncbi Perindopril: in congestive heart failure
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1367-77; discussion 1378-9. 2002
    ....
  21. ncbi Histrelin: in advanced prostate cancer
    Emma D Deeks
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:623-30. 2010
    ..No patients prematurely discontinued treatment because of adverse events, most of which were the consequence of hormone suppression...
  22. ncbi Mosapride in gastrointestinal disorders
    Monique P Curran
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:981-91. 2008
    ..Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients...
  23. ncbi Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis
    Therese M Chapman
    Adis International Limited, Auckland, New Zealand
    Drugs 63:2357-77. 2003
    ..In the meantime, available data suggest that bemiparin is an effective and useful addition to the available range of LMWHs for the prevention of VTE and treatment of DVT...
  24. ncbi Zoledronic acid : a review of its use in the management of bone metastases of malignancy
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:507-34. 2008
    ..Nevertheless, available clinical data indicate that zoledronic acid is an effective treatment option for the management of bone metastases of malignancy...
  25. ncbi Zonisamide: a review of its use in the management of partial seizures in epilepsy
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 19:347-67. 2005
    ..In the meantime, adjunctive therapy or monotherapy with zonisamide is a convenient, useful option for the management of partial seizures, including those refractory to other AEDs...
  26. ncbi Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2129-35; discussion 2136-7. 2005
    ..Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache...
  27. ncbi Solifenacin in overactive bladder syndrome
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 22:1061-9. 2005
    ..Solifenacin was generally well tolerated; the most frequently reported adverse events were dry mouth, constipation and blurred vision...
  28. ncbi Darifenacin: in the treatment of overactive bladder
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:885-92; discussion 893-4. 2004
    ..The most common adverse events were dry mouth and constipation. CNS tolerability appeared to be similar to that of placebo. Darifenacin had no adverse effect on cognitive function in healthy elderly volunteers...
  29. ncbi Anidulafungin
    David Murdoch
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2249-58; discussion 2259-60. 2004
    ..In the largest clinical trial to date, the most common treatment-related adverse events were phlebitis/thrombophlebitis, headache, nausea, vomiting and pyrexia...
  30. ncbi Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus
    Neil A Reynolds
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1957-74. 2004
    ..Insulin aspart is an effective and well tolerated alternative to regular human insulin and insulin lispro for the maintenance of glycaemic control in patients with type 1 or 2 diabetes...
  31. ncbi Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs 66:497-528. 2006
    ....
  32. ncbi Gadofosveset
    Sheridan Henness
    Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:851-7. 2006
    ..Gadofosveset was generally well tolerated in clinical trials, with most adverse events being mild or moderate in severity...
  33. ncbi Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Pharmacoeconomics 24:709-26. 2006
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of clopidogrel plus aspirin for up to 1 year as a cost-effective treatment relative to aspirin alone in this patient population...
  34. ncbi Intravenous ibandronate: in the treatment of osteoporosis
    Katherine F Croom
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1593-601; discussion 1602-3. 2006
    ..IV ibandronate was generally well tolerated in clinical trials. Treatment-related adverse events included musculoskeletal events and transient influenza-like symptoms, the latter mainly associated with the first dose...
  35. ncbi Orlistat: a review of its use in the management of obesity
    Sheridan Henness
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1625-56. 2006
    ..Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders...
  36. ncbi Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery
    Hannah C Evans
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:649-78. 2004
    ..Thus, on the basis of available evidence, ximelagatran/melagatran appears poised to play an important role in the prophylaxis of VTE in patients undergoing orthopaedic surgery...
  37. ncbi Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer
    Susan M Cheer
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:323-46. 2004
    ..Epoetin beta is an important option in the prevention of chemotherapy-induced anaemia, and a valid and valuable alternative to blood transfusion therapy for the treatment of cancer-related or chemotherapy-induced anaemia...
  38. ncbi Cetuximab: in the treatment of metastatic colorectal cancer
    Neil A Reynolds
    Adis International Limited, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:109-18; discussion 119-121. 2004
    ..In patients receiving cetuximab plus irinotecan, these were diarrhoea, asthenia, leucopenia and neutropenia...
  39. ncbi Bivalirudin: in patients with ST-segment elevation myocardial infarction
    Monique P Curran
    Adis, Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:909-18. 2010
    ....
  40. ncbi Mifamurtide: a review of its use in the treatment of osteosarcoma
    James E Frampton
    Adis, a Wolters Kluwer Business, Mairangi Bay, North Shore, Auckland, New Zealand
    Paediatr Drugs 12:141-53. 2010
    ..Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma...
  41. ncbi Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia
    Karly P Garnock-Jones
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:1333-53. 2011
    ..Eltrombopag is an effective treatment option for adult patients with chronic ITP and an increased risk of bleeding who are refractory to previous treatments, including splenectomy, as demonstrated in well designed clinical trials...
  42. ncbi Bexarotene
    M N Lowe
    Adis International Limited, Auckland, New Zealand
    Am J Clin Dermatol 1:245-50; discussion 251-2. 2000
    ..Reversible acute pancreatitis has occurred during oral bexarotene therapy. Adverse events associated with the topical formulation are limited to rash, pruritus, and pain...
  43. ncbi Denosumab: in cancer treatment-induced bone loss
    Victoria J Muir
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 24:379-86. 2010
    ..Denosumab treatment was generally well tolerated for up to 24 months in breast cancer patients and for up to 36 months in prostate cancer patients...
  44. ncbi Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults
    Lesley J Scott
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 24:387-406. 2010
    ....
  45. ncbi Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
    K Simpson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:301-21. 2000
    ..In those with excessive nasal congestion the combination of fexofenadine plus pseudoephedrine may be useful. In clinical trials fexofenadine is not associated with adverse cardiac or cognitive/psychomotor effects...
  46. ncbi Docetaxel: an update of its use in advanced breast cancer
    D P Figgitt
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:621-51. 2000
    ..The role of docetaxel in the adjuvant and neoadjuvant treatment of early breast cancer is being evaluated...
  47. ncbi Linezolid: a review of its use in the management of serious gram-positive infections
    C M Perry
    Adis International Limited, Auckland, New Zealand
    Drugs 61:525-51. 2001
    ..As the level of resistance to vancomycin increases among S. aureus and enterococci, linezolid is poised to play an important role in the management of serious gram-positive infections...
  48. ncbi Darbepoetin alfa
    T Ibbotson
    Adis International Limited, Auckland, New Zealand
    Drugs 61:2097-104; discussion 2105-6. 2001
    ..There have been no reports of immune responses to darbepoetin alfa in 1534 patients receiving treatment for up to 2 years...
  49. ncbi Linezolid
    D Clemett
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:815-27; discussion 828. 2000
    ..Linezolid is generally well tolerated and gastrointestinal disturbances are the most commonly occurring adverse events. No clinical evidence of adverse reactions as a result of monoamine oxidase inhibition has been reported...
  50. ncbi Ropinirole: a review of its use in the management of Parkinson's disease
    A J Matheson
    Adis International Limited, Auckland, New Zealand
    Drugs 60:115-37. 2000
    ..In addition, ropinirole is also efficacious in the management of more advanced Parkinson's disease in patients who are experiencing motor complications after long term levodopa use...
  51. ncbi Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:1623-47. 2011
    ..In conclusion, plerixafor is a valuable stem-cell mobilizer for use in combination with G-CSF in patients with lymphoma or MM, particularly in patients who are poor mobilizers or predicted poor mobilizers...
  52. ncbi Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders
    K M Hvizdos
    Adis International Limited, Auckland, New Zealand
    Drugs 60:1141-78. 2000
    ..The preparation is suitable for use in infants, children and adults with persistent asthma and in infants and children with croup...
  53. ncbi Topical aminolevulinic acid HCl photodynamic therapy
    D Ormrod
    Adis International Limited, Auckland, New Zealand
    Am J Clin Dermatol 1:133-9; discussion 140-1. 2000
    ..Localized erythema and edema were also common. No other significant adverse effects were noted and treatment was generally well tolerated. A well designed dermal applicator ensured perilesional skin was spared collateral damage...
  54. ncbi Spinosad: in pediculosis capitis
    Paul L McCormack
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Clin Dermatol 12:349-53. 2011
    ..Spinosad was generally well tolerated in clinical trials, with no severe or serious adverse events. Cutaneous and ocular irritation were the most common adverse events...
  55. ncbi Olanzapine: a review of its use in the treatment of bipolar I disorder
    N Bhana
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 15:871-904. 2001
    ..Available data support the choice of olanzapine as an option in the short-term management of mania in patients with bipolar I disorder with manic or mixed episodes, with or without psychotic features...
  56. ncbi Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma
    D Ormrod
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 17:477-96. 2000
    ..Nonetheless, dorzolamide combined with timolol in a single applicator system will be a useful addition to the treatment options for glaucoma, a leading cause of preventable blindness...
  57. ncbi Mirtazapine: a review of its use in major depression
    K J Holm
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:607-31. 1999
    ..Mirtazapine also appears to be useful in patients with depression who present with anxiety symptoms and sleep disturbance...
  58. ncbi Drotrecogin alfa (activated)
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 62:617-30; discussion 631-2. 2002
    ..Of the 210 deaths in patients with severe sepsis treated with drotrecogin alfa (activated) 24 microg/kg/h in the efficacy trial, four deaths due to haemorrhage and one due to cerebral oedema were possibly related to the study drug...
  59. ncbi Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies
    R N Brogden
    Adis International Limited, Auckland, New Zealand
    Drugs 54:634-50. 1997
    ..Fenoldopam may be particularly useful in patients who develop hypertension after coronary artery bypass graft surgery, but further studies are required to confirm its role in hypertensive emergency...
  60. ncbi Pramipexole. A review of its use in the management of early and advanced Parkinson's disease
    M Dooley
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 12:495-514. 1998
    ..The efficacy of pramipexole monotherapy in patients with early disease has also been demonstrated, although the use of dopamine agonists in early Parkinson's disease remains controversial...
  61. ncbi Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 24:797-800. 2010
    ....
  62. ncbi DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination
    Sohita Dhillon
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1021-58. 2010
    ....
  63. ncbi Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders
    A J Wagstaff
    Adis International Limited, Auckland, New Zealand
    Drugs 53:435-52. 1997
    ..Tizanidine, therefore, appears to be an attractive therapeutic alternative for patients with spasticity associated with cerebral or spinal damage...
  64. ncbi Donepezil
    H M Bryson
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 10:234-9; discussion 240-1. 1997
    ..No hepatotoxicity was reported after 12 weeks' treatment...
  65. ncbi Trastuzumab: in HER2-positive metastatic gastric cancer
    Jamie D Croxtall
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:2259-67. 2010
    ..In general, combination therapy with trastuzumab and chemotherapy was relatively well tolerated in patients with metastatic gastric cancer with no reports of new or unexpected adverse events...
  66. ncbi Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years)
    Sean T Duggan
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 27:597-605. 2010
    ....
  67. ncbi Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis
    Keri Wellington
    Adis International Limited, Auckland, New Zealand
    Drugs 62:817-40. 2002
    ..Pimecrolimus 1.0% cream provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis...
  68. ncbi Telmisartan: a review of its use in the management of hypertension
    Anna J Battershill
    Adis International Limited, Auckland, New Zealand
    Drugs 66:51-83. 2006
    ....
  69. ncbi Everolimus
    Therese M Chapman
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:861-72; discussion 873-4. 2004
    ..Everolimus has been associated with thrombocytopenia, leucopenia and elevated serum lipids and creatinine...
  70. ncbi Adalimumab: a review of its use in rheumatoid arthritis
    Lynne M Bang
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, PA 19067, USA
    BioDrugs 18:121-39. 2004
    ..The drug also retards the progression of structural joint damage, improves HR-QOL, and is generally well tolerated. Thus, adalimumab is a valuable new option for the treatment of DMARD-refractory adult rheumatoid arthritis...
  71. ncbi Voriconazole: in the treatment of invasive aspergillosis
    Richard B R Muijsers
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2655-64; discussion 2665-6. 2002
    ..02 both comparisons) fewer treatment-related adverse events or serious adverse events. The incidence of visual disturbances was significantly (p < 0.001) higher with voriconazole than amphotericin B treatment...
  72. ncbi Pioglitazone: a review of its use in type 2 diabetes mellitus
    John Waugh
    Adis International Limited, Auckland, New Zealand
    Drugs 66:85-109. 2006
    ..Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes...
  73. ncbi Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 28:231-54. 2010
    ....
  74. ncbi Remifentanil : a review of its analgesic and sedative use in the intensive care unit
    Anna J Battershill
    Adis International Limited, Auckland, New Zealand
    Drugs 66:365-85. 2006
    ..Thus, remifentanil is a welcome addition to the currently available pharmacological agents employed in the management of mechanically ventilated ICU patients...
  75. ncbi Lansoprazole: in the management of gastroesophageal reflux disease in children
    Lesley J Scott
    Adis International Inc, Langhorne, Pennsylvania 10947, USA
    Paediatr Drugs 5:57-61; discussion 62. 2003
    ..The drug is generally well tolerated in children with GERD. In the largest study, the most common treatment-related adverse events occurring during therapy were constipation and headache...
  76. ncbi Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension
    Richard B R Muijsers
    Adis International Limited, Auckland, New Zealand
    Drugs 62:2539-67. 2002
    ..Data from large clinical trials currently being conducted will assist in fully defining the role of trandolapril/verapamil SR as a cardio- and renoprotective agent...
  77. ncbi Glucosamine: a review of its use in the management of osteoarthritis
    Anna J Matheson
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:1041-60. 2003
    ..In addition, glucosamine has shown promising results in modifying the progression of arthritis over a 3-year period. Glucosamine may therefore prove to be a useful treatment option for osteoarthritis...
  78. ncbi Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections
    Malcolm J M Darkes
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Respir Med 2:175-201. 2003
    ..The reformulation modulates clarithromycin absorption kinetics thereby improving tolerability. Therefore, clarithromycin extended-release provides a useful option for the treatment of specific respiratory tract infections...
  79. ncbi Micafungin
    Blair Jarvis
    Adis International Limited, 41 Centorial Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:969-82; discussion 983-4. 2004
    ..5-900 mg/day; no histamine-like reactions occurred. Micafungin was as well tolerated as fluconazole, with numerically fewer micafungin recipients discontinuing treatment (4.2% vs 7.2%)...
  80. ncbi Reteplase: a review of its use in the management of thrombotic occlusive disorders
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:265-85. 2006
    ....
  81. ncbi Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women
    Susan M Cheer
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2639-55. 2005
    ....
  82. ncbi Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation
    David Murdoch
    Adis International Limited, Auckland, New Zealand
    Drugs 66:671-92. 2006
    ....
  83. ncbi Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus
    Christopher J Dunn
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 20:989-1025. 2002
    ..Further research into the pharmacoeconomic implications of insulin lispro use in the long term is needed, particularly with respect to effects on indirect costs and those associated with complications of diabetes mellitus...
  84. ncbi Amisulpride: a review of its use in the management of schizophrenia
    Kate McKeage
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:933-56. 2004
    ..Thus, amisulpride is an effective and well tolerated option for the first-line treatment of patients with acute schizophrenia as well as for those requiring long-term maintenance therapy...
  85. ncbi Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation
    Melissa Young
    Adis International Ltd, Auckland, New Zealand
    Pharmacoeconomics 20:675-713. 2002
    ..Additional pharmacoeconomic analyses of mycophenolate mofetil are also needed in other types of solid organ transplantation...
  86. ncbi Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Vicki Oldfield
    Wolters Kluwer Health Adis, North Shore, Auckland, New Zealand
    BioDrugs 23:125-35. 2009
    ..The tolerability profile of golimumab was generally consistent with that of other anti-TNF agents...
  87. ncbi Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder
    Nishan S Gunasekara
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1217-51. 2002
    ..In addition, intramuscular ziprasidone shows efficacy and good tolerability in the treatment of acute agitation associated with psychotic disorders...
  88. ncbi Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease
    Katherine A Lyseng-Williamson
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:273-82; discussion 283-4. 2002
    ..Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD...
  89. ncbi Atomoxetine
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:407-15; discussion 416-7. 2003
    ..The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled substance in the US...
  90. ncbi Tipranavir: a review of its use in the management of HIV infection
    Jennifer S Orman
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1435-63. 2008
    ..Thus, tipranavir, administered with ritonavir, is an effective treatment option for use in the combination therapy of adults with HIV-1 infection who have been previously treated with other antiretroviral drugs...
  91. ncbi Spotlight on gefitinib in non-small-cell lung cancer
    James E Frampton
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Pharmacogenomics 5:133-6. 2005
    ..Further studies are needed to fully elucidate the clinical implications of EGFR mutations and to identify patients likely to benefit from EGFR-targeted therapy...
  92. ncbi Azelaic acid 15% gel: in the treatment of papulopustular rosacea
    James E Frampton
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:57-64. 2004
    ....
  93. ncbi Selegiline transdermal system: in the treatment of major depressive disorder
    James E Frampton
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:257-65; discussion 266-7. 2007
    ..The incidence of sexual adverse effects and weight gain was low and similar to that with placebo...
  94. ncbi DTaP(5)-IPV-Hib vaccine (Pediacel®)
    James E Frampton
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Paediatr Drugs 13:401-15. 2011
    ..It had an adverse event profile generally similar to that of other combination vaccines based on diphtheria, tetanus and acellular pertussis vaccine, including Infanrix®-IPV+Hib and Infanrix® hexa...
  95. ncbi Tigecycline
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2623-35; discussion 2636-7. 2005
    ....
  96. ncbi Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer
    James E Frampton
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:2475-92. 2004
    ..These findings have been supported by observations from a global compassionate-use programme. Ongoing or planned clinical trials are designed to confirm and/or further define the role of the drug in the above and other clinical settings...
  97. ncbi Selegiline transdermal system in major depressive disorder: profile report
    James E Frampton
    Wolters Kluwer Health/Adis, Auckland, New Zealand
    CNS Drugs 21:521-4. 2007
  98. ncbi Duloxetine: a review of its use in the treatment of major depressive disorder
    James E Frampton
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    CNS Drugs 21:581-609. 2007
    ..It also appears to be an attractive option for MDD patients presenting with painful physical symptoms...
  99. ncbi Aliskiren: a review of its use in the management of hypertension
    James E Frampton
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:1767-92. 2007
    ..Nonetheless, by offering a new approach to the blockade of the RAS, aliskiren provides a useful addition to the therapeutic options available to treat patients with mild to moderate hypertension...
  100. ncbi Pregabalin: in the treatment of painful diabetic peripheral neuropathy
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2813-20; discussion 2821. 2004
    ..Pregabalin was well tolerated in DPN patients; mild-to-moderate dizziness, somnolence and peripheral oedema were the most common adverse events...
  101. ncbi Hexyl aminolevulinate: in the detection of bladder cancer
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    Drugs 66:571-8; discussion 579-80. 2006
    ..Hexyl aminolevulinate cystoscopy is well tolerated as an adjunct to standard cystoscopy; adverse events were those typically associated with standard cystoscopy/biopsy (e.g. postoperative pain)...